ArticleThe Journal of infectious diseases2021
Human Papillomavirus Genotype Replacement: Still Too Early to Tell?
Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.The Lancet. Oncology · 2022Trial
- Predicting optimal impact interventions in the post-HPV vaccination world.International journal of cancer · 2026Review
- Circulating genotypes of human papillomavirus in adult women of reproductive age from the Boeny region of Madagascar: a cross-sectional study to explore needs and opportunities for HPV vaccination in the country.BMC infectious diseases · 2026Article
- Co-infection of multiple human papillomavirus genotypes and its effects on symptomatic risks and transmission dynamics: an integrated epidemiological and modelling study in Fujian, China.BMJ public health · 2026Article
- HPV Type Replacement After HPV Vaccination.Current topics in microbiology and immunology · 2026Review
- Ten-year evaluation of HPV vaccine influence on non-vaccine-type-related cervical infections and precancers in Chinese females: follow-up from a randomized control trial.Journal of the National Cancer Center · 2025Article
- Changes in Genital Human Papillomavirus (HPV) Prevalence During 12 Years of Girls-Only Bivalent HPV Vaccination: Results From a Biennial Repeated Cross-sectional Study.The Journal of infectious diseases · 2025Article
- Persistently high prevalence of HPV16 and rising prevalence of non-16/18 HR-HPV genotypes in cervical precancer and cancer in Latvia in 2016-2024 shape the severity of cervical disease.Frontiers in oncology · 2025Article
- Pattern of multiple human papillomavirus infection and type competition: An analysis in healthy Chinese women aged 18-45 years.Human vaccines & immunotherapeutics · 2024Article
- Impact of single-dose HPV vaccination on HPV 16 and 18 prevalence in South African adolescent girls with and without HIV.Journal of the National Cancer Institute. Monographs · 2024Article
- HPV specificity and multiple infections and association with cervical cytology in Chongqing, China: a cross-sectional study.BMC infectious diseases · 2024Article
- Update on Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology.Viruses · 2024Review
- An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report.Preventive medicine reports · 2023Article
- Ability of epidemiological studies to monitor HPV post-vaccination dynamics: a simulation study.Epidemiology and infection · 2023Article
- Associations of human papillomavirus genotypes and cervical vascular abnormality in a cohort of women underwent colposcopy, a retrospective study of 6716 patients.Frontiers in oncology · 2023Article
- Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.Frontiers in public health · 2023Article
- Can breeders prevent pathogen adaptation when selecting for increased resistance to infectious diseases?Genetics, selection, evolution : GSE · 2022Article
- Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines.Applied health economics and health policy · 2022Article
- Article
- Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology.Viruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough human papillomavirus (HPV) vaccines are highly efficacious in protecting against HPV infections and related diseases, vaccination may trigger replacement by nontargeted genotypes if these compete with the vaccine-targeted types. HPV genotype replacement has been deemed unlikely, based on the lack of systematic increases in the prevalence of nonvaccine-type (NVT) infection in the first decade after vaccination, and on the presence of cross-protection for some NVTs.
methodsTo investigate whether type replacement can be inferred from early postvaccination surveillance, we constructed a transmission model in which a vaccine type and an NVT compete through infection-induced cross-immunity. We simulated scenarios of different levels of cross-immunity and vaccine-induced cross-protection to the NVT. We validated whether commonly used measures correctly indicate type replacement in the long run.
resultsType replacement is a trade-off between cross-immunity and cross-protection; cross-immunity leads to type replacement unless cross-protection is strong enough. With weak cross-protection, NVT prevalence may initially decrease before rebounding into type replacement, exhibiting a honeymoon period. Importantly, vaccine effectiveness for NVTs is inadequate for indicating type replacement.
conclusionsAlthough postvaccination surveillance thus far is reassuring, it is still too early to preclude type replacement. Monitoring of NVTs remains pivotal in gauging population-level impacts of HPV vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.